Arrowstreet Capital
URGN icon

Arrowstreet Capital’s UroGen Pharma URGN Stock Holding History

Arrowstreet Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,932
Closed -$91K – 1517
2018
Q3 		$91K Sell
1,932
-19,218
-91% -$893K ﹤0.01% 1051
2018
Q2 		$1.05M Buy
+21,150
New +$1.23M ﹤0.01% 793

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arrowstreet Capital's URGN Position: Q4 2018 in Review

Arrowstreet Capital sold out of UroGen Pharma (URGN) in Q4 2018, closing a stake of 1,932 shares — an estimated $91K sold.

Arrowstreet Capital first reported a position in URGN in Q2 2018 and held it in 2 quarters. The position peaked at $1.05M in Q2 2018. 63 funds tracked by Wall St. Rank hold URGN as of Q4 2018.

  • Arrowstreet Capital reported no remaining UroGen Pharma position as of Q4 2018 after selling out during the quarter.
  • Arrowstreet Capital sold 1,932 UroGen Pharma shares in Q4 2018, an estimated $91K.
  • Arrowstreet Capital first reported a position in UroGen Pharma in Q2 2018 and held it in 2 quarters.
  • Arrowstreet Capital's UroGen Pharma position peaked at $1.05M in Q2 2018.
  • 63 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2018.

Based on Arrowstreet Capital's 13F filing for Q4 2018, filed 14 Feb 2019.